{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T13:24:17Z","timestamp":1794057857970,"version":"4.8.0"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jtct.2026.10.011","type":"journal-article","created":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T22:13:34Z","timestamp":1791756814000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Considerations for Improving Equity and Access to Chimeric Antigen Receptor-T Therapies"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4475-0255","authenticated-orcid":false,"given":"Eddie H.P.","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4368-2502","authenticated-orcid":false,"given":"Mickey B.C.","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2026.10.011_bib0001","article-title":"Perspectives on the use and availability of chimeric antigen receptor T cells (CAR-T) and cell therapies: a worldwide cross-sectional survey by the worldwide network for blood and marrow transplantation (WBMT)","volume":"73","author":"Tan","year":"2025","journal-title":"Curr Res Transl Med"},{"key":"10.1016\/j.jtct.2026.10.011_bib0002","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/s41577-025-01228-4","article-title":"Clearing the hurdles for CAR-T cell treatment","volume":"25","author":"Rouce","year":"2025","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jtct.2026.10.011_bib0003","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1136\/bmjinnov-2020-000425","article-title":"Patient access to gene therapy medicinal products: a comprehensive review","volume":"7","author":"Carvalho","year":"2021","journal-title":"BMJ Innov"},{"key":"10.1016\/j.jtct.2026.10.011_bib0004","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jtct.2025.05.012","article-title":"Setting up a chimeric antigen receptor T cell therapy program: a framework for delivery from the worldwide network for blood & marrow transplantation","volume":"31","author":"Ahmed","year":"2025","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2026.10.011_bib0005","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1182\/blood.2025030872","article-title":"Global access to commercial CAR T-cell therapies: a cross-sectional study of health technology assessment across the G20 countries","volume":"147","author":"Ge","year":"2026","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.10.011_bib0006","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1182\/blood.2025032585","article-title":"Access to CAR T-cell therapy across diverse global markets","volume":"147","author":"Jenei","year":"2026","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.10.011_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.healthpol.2024.105153","article-title":"Availability and financing of CAR-T cell therapies: a cross-country comparative analysis","volume":"149","author":"Litvinova","year":"2024","journal-title":"Health Policy"},{"key":"10.1016\/j.jtct.2026.10.011_bib0008","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1186\/s12913-023-09494-5","article-title":"How are health technology assessment bodies responding to the assessment challenges posed by cell and gene therapy?","volume":"23","author":"Drummond","year":"2023","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.jtct.2026.10.011_bib0009","doi-asserted-by":"crossref","DOI":"10.1200\/GO-25-00760","article-title":"Improving chimeric antigen receptor T access in Latin America: promises, barriers, and a call to action","volume":"12","author":"Wills","year":"2026","journal-title":"JCO Glob Oncol"},{"key":"10.1016\/j.jtct.2026.10.011_bib0010","article-title":"CAR-T in resource-limited regions","volume":"2","author":"Cl\u00e9","year":"2026","journal-title":"Blood Glob Hematol"},{"key":"10.1016\/j.jtct.2026.10.011_bib0011","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0256122","article-title":"COVID-19 vaccine acceptance and beliefs among Black and Hispanic Americans","volume":"16","author":"Kricorian","year":"2021","journal-title":"PLOS ONE"},{"key":"10.1016\/j.jtct.2026.10.011_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.bict.2025.100007","article-title":"Access and outcomes of racial and ethnic minority populations receiving commercial anti-BCMA CART for myeloma","volume":"1","author":"Paruzzo","year":"2025","journal-title":"Blood Immunol Cell Ther"},{"key":"10.1016\/j.jtct.2026.10.011_bib0013","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1089\/hum.2014.030","article-title":"Prevailing public perceptions of the ethics of gene therapy","volume":"25","author":"Robillard","year":"2014","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.jtct.2026.10.011_bib0014","doi-asserted-by":"crossref","first-page":"e786","DOI":"10.1016\/S2352-3026(22)00226-5","article-title":"Access to and affordability of CAR T-cell therapy in multiple myeloma: an EBMT position paper","volume":"9","author":"Gagelmann","year":"2022","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtct.2026.10.011_bib0015","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s40290-023-00480-0","article-title":"The cost of biotech innovation: exploring research and development costs of cell and gene therapies","volume":"37","author":"Sabatini","year":"2023","journal-title":"Pharm Med"},{"key":"10.1016\/j.jtct.2026.10.011_bib0016","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s11899-021-00635-3","article-title":"Balancing quality, cost, and access during delivery of newer cellular and immunotherapy treatments","volume":"16","author":"Geethakumari","year":"2021","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.jtct.2026.10.011_bib0017","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s41669-025-00614-x","article-title":"Cost-effectiveness of chimeric antigen receptor (CAR) T-cell therapy for blood cancers: an updated systematic review","volume":"10","author":"Patel","year":"2026","journal-title":"Pharmacoecon Open"},{"key":"10.1016\/j.jtct.2026.10.011_bib0018","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/jamainternmed.2022.4924","article-title":"Association between US drug price and measures of efficacy for oncology drugs approved by the US Food and Drug Administration from 2015 to 2020","volume":"182","author":"Miljkovi\u0107","year":"2022","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jtct.2026.10.011_bib0019","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-071710","article-title":"High drug prices are not justified by industry\u2019s spending on research and development","volume":"380","author":"Angelis","year":"2023","journal-title":"BMJ"},{"key":"10.1016\/j.jtct.2026.10.011_bib0020","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s42977-020-00025-5","article-title":"Pharmaceutical drug development: high drug prices and the hidden role of public funding","volume":"72","author":"Annett","year":"2021","journal-title":"Biol Futura"},{"key":"10.1016\/j.jtct.2026.10.011_bib0021","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/TP.0000000000005222","article-title":"Santander global summit in transplantation: supporting global convergence in the shared goals of sufficiency, transparency, and oversight","volume":"109","author":"Dom\u00ednguez-Gil","year":"2025","journal-title":"Transplantation"},{"key":"10.1016\/j.jtct.2026.10.011_bib0022","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/TP.0000000000005169","article-title":"Promoting equitable and affordable patient access to safe and effective innovations in donation and transplantation of substances of human origin and derived therapies","volume":"109","author":"Cuende","year":"2025","journal-title":"Transplantation"},{"key":"10.1016\/j.jtct.2026.10.011_bib0023","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S1474-4422(23)00194-1","article-title":"Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b\/2a study","volume":"22","author":"Granit","year":"2023","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jtct.2026.10.011_bib0024","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41571-023-00832-4","article-title":"CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn","volume":"21","author":"Albelda","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jtct.2026.10.011_bib0025","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1016\/S0140-6736(23)01126-1","article-title":"CAR T-cell therapy in autoimmune diseases","volume":"402","author":"Schett","year":"2023","journal-title":"The Lancet"},{"key":"10.1016\/j.jtct.2026.10.011_bib0026","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1038\/s41591-025-03767-8","article-title":"Stem cell therapies for diabetes","volume":"31","author":"Chen","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.jtct.2026.10.011_bib0027","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/s41392-025-02313-9","article-title":"Mesenchymal stem cells in treating human diseases: molecular mechanisms and clinical studies","volume":"10","author":"Han","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.jtct.2026.10.011_bib0028","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.3390\/cells10112845","article-title":"From hematopoietic stem cell transplantation to chimeric antigen receptor therapy: advances, limitations and future perspectives","volume":"10","author":"Voynova","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.jtct.2026.10.011_bib0029","doi-asserted-by":"crossref","first-page":"lsac027","DOI":"10.1093\/jlb\/lsac027","article-title":"On CAR-ts, decentralized in-house models, and the hospital exception. Routes for sustainable access to innovative therapies","volume":"9","author":"Arnaudo","year":"2022","journal-title":"J Law Biosci"},{"key":"10.1016\/j.jtct.2026.10.011_bib0030","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1186\/s12967-025-06400-x","article-title":"Surveying local CAR T-cell manufacturing processes to facilitate standardization and expand accessibility","volume":"23","author":"Gupta","year":"2025","journal-title":"J Transl Med"},{"key":"10.1016\/j.jtct.2026.10.011_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymthe.2025.09.049","article-title":"Overcoming barriers to commercially pre-viable gene and cell therapies for rare and ultra-rare diseases","volume":"33","author":"Barrett","year":"2025","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtct.2026.10.011_bib0032","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1056\/NEJMsr1715626","article-title":"Balancing safety and innovation for cell-based regenerative medicine","volume":"378","author":"Marks","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2026.10.011_bib0033","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2025.1640275","article-title":"Stem\/progenitor cell-based therapy for Duchenne muscular dystrophy","volume":"13","author":"Tominari","year":"2025","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.jtct.2026.10.011_bib0034","unstructured":"PMDA. Regenerative Medical Products. Pharm. Med. Devices Agency PMDAhttps:\/\/www.pmda.go.jp\/english\/review-services\/reviews\/0003.html (accessed Aug 30, 2025). Japan"},{"key":"10.1016\/j.jtct.2026.10.011_bib0035","series-title":"The ISSCR Encourages Japanese Policymakers to Increase Oversight of Regenerative Medicine Interventions","year":"2025"},{"key":"10.1016\/j.jtct.2026.10.011_bib0036","unstructured":"JSRM. YOKOHAMA declaration 2025. 2025. https:\/\/www.amed.go.jp\/content\/000140595.pdf (accessed Aug 30, 2025)."},{"key":"10.1016\/j.jtct.2026.10.011_bib0037","series-title":"Woman Dies After Unproven Regenerative Medicine at Clinic in Japan","author":"Knoepfler","year":"2025"},{"key":"10.1016\/j.jtct.2026.10.011_bib0038","series-title":"(Translated Title) Ministry of Health, Labor and Welfare Orders Suspension of Treatment After Patient Dies From Cell Therapy Administered Under Elective Medical Care","year":"2025"},{"key":"10.1016\/j.jtct.2026.10.011_bib0039","unstructured":"EBMT. Joint statement on the hospital exemption for ATMPs. 2025; published online Nov 10.https:\/\/www.ebmt.org\/ebmt\/documents\/joint-statement-hospital-exemption-atmps (accessed Nov 25, 2025)."},{"key":"10.1016\/j.jtct.2026.10.011_bib0040","unstructured":"GoCART. GoCART coalition. 2025. https:\/\/thegocartcoalition.com\/(accessed Nov 26, 2025)."},{"key":"10.1016\/j.jtct.2026.10.011_bib0041","series-title":"Human Medicines Modular Manufacture and Point of Care Regulations 2025: Overview","year":"2025"},{"key":"10.1016\/j.jtct.2026.10.011_bib0042","unstructured":"Ministry of Health Singapore. Licence conditions for all acute hospital service, outpatient dental service and outpatient medical service licensees administering or intending to administer cell, tissue and gene therapy products manufactured in house by healthcare institutions. 2023. https:\/\/isomer-user-content.by.gov.sg\/7\/bc466d1d-44d1-4a5f-bfc5-dcf1da4eca1b\/lcs-on-administering-cell-tissue-and-gene-therapy-products_1-0.pdf (accessed Aug 30, 2025)."},{"key":"10.1016\/j.jtct.2026.10.011_bib0043","unstructured":"HSA. HSA | Import and Supply of Unregistered Class 2 CTGTP. Health Sci. Auth. HSA. https:\/\/www.hsa.gov.sg\/ctgtp\/registration\/sar\/unregistered-CTGTP (accessed Aug 30, 2025). Singapore"},{"key":"10.1016\/j.jtct.2026.10.011_bib0044","unstructured":"Asia-Pacific Economic Cooperation. Advanced therapy and biotherapeutic products. APEC.https:\/\/www.apec.org\/rhsc\/rhsc-priority-work-areas\/advanced-therapy-products (accessed Sept 6, 2025)."},{"key":"10.1016\/j.jtct.2026.10.011_bib0045","series-title":"Considerations in Developing a Regulatory Framework for Human Cells and Tissues and for Advance Therapy Medicinal Products, Annex 3, TRS 1048","year":"2023"},{"key":"10.1016\/j.jtct.2026.10.011_bib0046","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2025.1595213","article-title":"Beyond human limits: the ethical, social, and regulatory implications of human enhancement","volume":"12","author":"Gerardi","year":"2025","journal-title":"Front Med"},{"key":"10.1016\/j.jtct.2026.10.011_bib0047","article-title":"Cell therapy products are revolutionizing multiple therapeutic areas; to maintain this pace of innovation, manufacturing solutions must adapt","volume":"20","author":"Abraham","year":"2021","journal-title":"Curr Opin Biomed Eng"},{"key":"10.1016\/j.jtct.2026.10.011_bib0048","doi-asserted-by":"crossref","DOI":"10.1016\/j.hlife.2025.07.001","article-title":"Enabling manufacture and access to advanced therapy medicinal products in low- and middle-income countries","author":"Campos De Carvalho","year":"2025","journal-title":"hLife"},{"key":"10.1016\/j.jtct.2026.10.011_bib0049","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-024-03231-z","article-title":"CAR-T and cellular gene therapies are too expensive","volume":"30","author":"Dropuli\u0107","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.jtct.2026.10.011_bib0050","doi-asserted-by":"crossref","first-page":"e236","DOI":"10.1016\/S2352-3026(25)00040-7","article-title":"CAR T-cell therapy in LMICs: approval of talicabtagene autoleucel in India","volume":"12","author":"Paruzzo","year":"2025","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtct.2026.10.011_bib0051","first-page":"121","article-title":"A discount on the cost of cancer: India\u2019s homegrown CAR-T cell therapy","volume":"7","author":"Rehman","year":"2024","journal-title":"Blood Cell Ther"},{"key":"10.1016\/j.jtct.2026.10.011_bib0052","unstructured":"Pilla V. Bengaluru company launches low-cost treatment for blood cancer \u2013 the economic times. 2025.https:\/\/economictimes.indiatimes.com\/industry\/healthcare\/biotech\/healthcare\/bengaluru-company-launches-low-cost-treatment-for-blood-cancer\/articleshow\/117379168.cms?from=mdr (accessed Sept 6, 2025)."},{"key":"10.1016\/j.jtct.2026.10.011_bib0053","doi-asserted-by":"crossref","DOI":"10.1038\/s41409-026-03044-3","article-title":"Decentralized CAR-T production: clinical, economic, and regulatory perspectives. worldwide network for blood & marrow transplantation (WBMT) special article","author":"Nasiri","year":"2026","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.10.011_bib0054","doi-asserted-by":"crossref","DOI":"10.3389\/frhem.2026.1891877","article-title":"Commentary: \u201cBridging Innovation and Equity: the Evolving Landscape of CAR T-cell Therapy Access in Brazil\u201d the Uruguayan pediatric experience","volume":"5","author":"Pereira","year":"2026","journal-title":"Front Hematol"},{"key":"10.1016\/j.jtct.2026.10.011_bib0055","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1097\/TP.0000000000004527","article-title":"Addressing risks derived from the commodification of substances of human origin: a European proposal applicable worldwide","volume":"107","author":"Cuende","year":"2023","journal-title":"Transplantation"},{"key":"10.1016\/j.jtct.2026.10.011_bib0056","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcyt.2026.102884","article-title":"Rethinking CAR-T manufacturing paradigms: terminology, operational considerations, and economic trade-offs","volume":"28","author":"McCann","year":"2026","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jtct.2026.10.011_bib0057","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/j.jtct.2025.01.020","article-title":"Manufacturing characteristics and early outcomes of a tandem aCD22-aCD19 CAR-T therapy for childhood and adult relapsed\/refractory acute precursor B lymphoblastic leukemia","volume":"31","author":"Su-fern Seng","year":"2025","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2026.10.011_bib0058","doi-asserted-by":"crossref","DOI":"10.1158\/2643-3230.BCD-26-0115","article-title":"A phase I\/II trial of anti-CD22\/CD19 CAR-T cell therapy, CART2219.1, in adult and pediatric relapsed\/refractory B-ALL","author":"Seng","year":"2026","journal-title":"Blood Cancer Discov"},{"key":"10.1016\/j.jtct.2026.10.011_bib0059","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.jcyt.2017.07.005","article-title":"Decentralized manufacturing of cell and gene therapies: overcoming challenges and identifying opportunities","volume":"19","author":"Harrison","year":"2017","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jtct.2026.10.011_bib0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcyt.2026.102939","article-title":"Overcoming access barriers in European CAR-T therapy: the role of decentralized manufacturing and the EASYGEN framework","volume":"28","author":"Griebling","year":"2026","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jtct.2026.10.011_bib0061","doi-asserted-by":"crossref","first-page":"4502","DOI":"10.1182\/bloodadvances.2025016053","article-title":"An ethical allocation scheme for scarce gene therapies in sickle cell disease and transfusion-dependent \u03b2-thalassemia","volume":"9","author":"Kelkar","year":"2025","journal-title":"Blood Adv"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726008006?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726008006?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T12:41:13Z","timestamp":1794055273000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636726008006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":61,"alternative-id":["S2666636726008006"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.10.011","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Considerations for Improving Equity and Access to Chimeric Antigen Receptor-T Therapies","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.10.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}